Biovica has signed a framework agreement and an initial work order of approximately SEK 0,8 million with an American Tier-1 biopharma company, the fifth in the US. The agreement concerns DiviTum TKa-testing in a Phase I study for next-generation CDK4/6 inhibitors. This underscores the increasing relevance of the TKa biomarker test in the development of advanced cancer treatments, according to the CEO Anders Rylander.